207 related articles for article (PubMed ID: 22039089)
1. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
[TBL] [Abstract][Full Text] [Related]
2. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Chen RA; Tu Y; Cao Y; Liu L; Liang Y
J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
13. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
14. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
16. Part II: role of maintenance therapy in transplant-ineligible patients.
Palumbo A; Mina R
J Natl Compr Canc Netw; 2013 Jan; 11(1):43-9. PubMed ID: 23307980
[TBL] [Abstract][Full Text] [Related]
17. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
18. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
